Clinical Trials Directory

Trials / Completed

CompletedNCT02215954

A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing

A Phase III, Randomized, Assessor-Blinded, Parallel-Group, Multi-Centre, Clinical Study With FE 999169 for Oral Administration Versus Niflec® for Colon Cleansing: J-CLEAR

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
637 (actual)
Sponsor
Ferring Pharmaceuticals · Industry
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

To demonstrate non inferiority of a) "FE 999169 Split Dosing Schedule" (one dose on the day before and the second dose on the day of colonoscopy) and b) "FE 999169 Day Before Dosing Schedule" (two doses on the day before colonoscopy) to " Niflec On the Day Dosing Schedule" in subjects requiring colonoscopy.

Detailed description

This was a phase III, randomized, assessor-blinded, parallel-arm, multicenter, study in Japanese patients. Patients, who signed an informed consent and fulfilled all screening criteria, were randomized in a 1:1:1 ratio to one of the following 3 treatment groups: "FE 999169 Split Dosing Schedule", "FE 999169 Day Before Dosing Schedule" and " Niflec On the Day Dosing Schedule" in subjects requiring colonoscopy.

Conditions

Interventions

TypeNameDescription
DRUGFE 999169FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
DRUGNiflecNiflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.

Timeline

Start date
2014-09-01
Primary completion
2014-12-01
Completion
2014-12-01
First posted
2014-08-13
Last updated
2017-07-17
Results posted
2017-07-17

Locations

4 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT02215954. Inclusion in this directory is not an endorsement.